OVERVIEW

Sermorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH), designed to stimulate natural growth hormone (GH) secretion. It has been widely researched for its clinical applications in GH assessment and its potential benefits in cardiovascular health, cognitive function, and metabolic regulation.

Studies suggest Sermorelin may:

• Increase bone density, supporting skeletal health.
• Reduce scarring, aiding in tissue healing and wound repair.
• Enhance renal function, potentially benefiting kidney health.
• Support cognitive function and fight dementia, by promoting neuronal protection.
• Reduce seizure activity, through GABA receptor interactions.
• Improve cardiovascular health, by aiding heart tissue repair after damage.

Unlike direct GH therapy, Sermorelin preserves the body’s natural GH regulation, reducing the risk of overdosing, joint pain, and GH desensitization.

RESEARCH

Sermorelin and Heart Health

• Research in pig models demonstrated that Sermorelin reduces cardiac remodeling following a heart attack.
• Mechanisms include:
  • Decreasing cardiomyocyte (heart cell) death.
  • Enhancing extracellular matrix production, supporting tissue healing.
  • Stimulating new blood vessel growth, improving circulation.
  • Reducing inflammation, lowering further heart damage risk.
• Potential application: Post-myocardial infarction recovery and heart failure management.

Sermorelin and Epilepsy

• Studies suggest Sermorelin activates GABA receptors, which help suppress seizures.
• Animal models of epilepsy showed that GHRH analogues reduce seizure activity.
• Potential application: Adjunctive therapy for seizure disorders.

Sermorelin and Sleep Regulation

• Sermorelin may influence orexin, a key neurochemical regulating wakefulness and sleep cycles.
• Exogenous administration of Sermorelin has been linked to more stable sleep patterns.
• Potential application: Treatment for sleep disturbances and optimization of sleep quality.

Sermorelin as a Preferred Alternative to GH Therapy

Unlike direct GH administration, Sermorelin:

• Preserves physiological GH feedback mechanisms, reducing the risk of GH overdose and dysregulation.
• Does not cause tachyphylaxis (desensitization), meaning the body does not lose sensitivity to its effects over time.
• Has a lower risk of side effects, such as edema, joint pain, and metabolic imbalances.
• Potential application: Safer alternative for individuals requiring GH optimization.

STRUCTURE

• Molecular Formula: C₁₄₉H₂₄₆N₄₄O₄₂S
• Molecular Weight: 3357.933 g/mol
• Amino Acid Sequence:
  Tyr-DL-Ala-DL-Asp-DL-Ala-DL-xiIle-DL-Phe-DL-xiThr-DL-Asn-DL-Ser-DL-Tyr-DL-Arg-DL-Lys-DL-Val-DL-Leu-Gly-DL-Gln-DL-Leu-DL-Ser-DL-Ala-DL-Arg-DL-Lys-DL-Leu-DL-Leu-DL-Gln-DL-Asp-DL-xiIle-DL-Met-DL-Ser-DL-Arg
• CAS Registry Number: 86168-78-7

CITATIONS

1. L. L. Bagno et al. Growth Hormone–Releasing Hormone Agonists Reduce Myocardial Infarct Scar in Swine With Subacute Ischemic Cardiomyopathy. J. Am. Heart Assoc. Cardiovasc. Cerebrovasc. Dis. (2015).
2. R. M. Kanashiro-Takeuchi et al. New therapeutic approach to heart failure due to myocardial infarction based on targeting growth hormone-releasing hormone receptor. Oncotarget (2015).
3. S. Tang et al. Interactions between GHRH and GABAARs in the brains of patients with epilepsy and in animal models of epilepsy. Sci. Rep. (2017).
4. B. S. Shepherd et al. Endocrine and orexigenic actions of growth hormone secretagogues in rainbow trout (Oncorhynchus mykiss). Comp. Biochem. Physiol. A. Mol. Integr. Physiol. (2007).
5. R. F. Walker. Sermorelin: A better approach to management of adult-onset growth hormone insufficiency? Clin. Interv. Aging (2006).
6. S. T. Wahid et al. Partial tachyphylaxis to somatostatin (SST) analogues in a patient with acromegaly: the role of SST receptor desensitisation and circulating antibodies to SST analogues. Eur. J. Endocrinol. (2002).